KDE40105
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
LY3437943
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis., PMID:40489581
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis., PMID:40471293
Contractile effects of retatrutide in isolated mouse atrial preparations., PMID:40464942
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials., PMID:40291085
Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials., PMID:40207414
Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review., PMID:40206909
Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment., PMID:40126003
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression., PMID:40094000
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities., PMID:40081498
[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]., PMID:40042613
Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis., PMID:40040445
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines., PMID:40022548
Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials., PMID:39980735
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis., PMID:39968298
Emerging pharmacotherapies for obesity: A systematic review., PMID:39952695
Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis., PMID:39911047
Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP., PMID:39868848
Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis., PMID:39817343
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado., PMID:39776466
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials., PMID:39761578
Why are we still in need for novel anti-obesity medications?, PMID:39726721
The First Triple Agonist for Antiobesity: Retatrutide., PMID:39724554
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article., PMID:39676791
The power of three: Retatrutide's role in modern obesity and diabetes therapy., PMID:39515565
The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity., PMID:39507873
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation., PMID:39481534
Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review., PMID:39458963
Retatrutide., PMID:39429457
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care., PMID:39335551
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials., PMID:39318607
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials., PMID:39305981
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology., PMID:39259982
Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice., PMID:39212900
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy., PMID:39125772
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases., PMID:39096466
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide., PMID:39019866
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity., PMID:38984950
Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials., PMID:38976545
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial., PMID:38858523
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity., PMID:38843460
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?, PMID:38753454
Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review., PMID:38723646
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?, PMID:38687506
Advancements in the management of obesity: a review of current evidence and emerging therapies., PMID:38685693
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions., PMID:38681750
Top studies of 2023 relevant to primary care: From the PEER team., PMID:38626998
Gut hormones and appetite regulation., PMID:38511400
An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update., PMID:38471973
The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases., PMID:38471571
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity., PMID:38367045
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
